↓ Skip to main content

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

Overview of attention for article published in Journal of Hematology & Oncology, April 2012
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
30 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Published in
Journal of Hematology & Oncology, April 2012
DOI 10.1186/1756-8722-5-18
Pubmed ID
Authors

Azra Raza, Naomi Galili, Deborah Mulford, Scott E Smith, Gail L Brown, David P Steensma, Roger M Lyons, Ralph Boccia, Mikkael A Sekeres, Guillermo Garcia-Manero, Ruben A Mesa

Abstract

Ezatiostat, a glutathione S-transferase P1-1 inhibitor, promotes the maturation of hematopoietic progenitors and induces apoptosis in cancer cells.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 3%
Unknown 29 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 23%
Student > Ph. D. Student 7 23%
Student > Bachelor 3 10%
Student > Postgraduate 2 7%
Librarian 1 3%
Other 3 10%
Unknown 7 23%
Readers by discipline Count As %
Medicine and Dentistry 13 43%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Psychology 1 3%
Computer Science 1 3%
Unknown 13 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 May 2012.
All research outputs
#20,156,537
of 22,664,644 outputs
Outputs from Journal of Hematology & Oncology
#1,032
of 1,187 outputs
Outputs of similar age
#147,466
of 162,569 outputs
Outputs of similar age from Journal of Hematology & Oncology
#9
of 9 outputs
Altmetric has tracked 22,664,644 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,187 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 162,569 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one.